Higher, But Cautious

Biotech stocks are climbing high, but Reuters' Deena Beasley writes that a nearly 50 percent increase in the last year has stoked worries about a bubble. She notes that the Nasdaq Biotech Index is up 45 percent as compared to last year and the Pharmaceutical Index is similarly up 32 percent, while during the same timeframe, the S&P 500 Index gained 25 percent.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.